<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292535</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000804</org_study_id>
    <nct_id>NCT04292535</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Combining Intranasal Insulin &amp; Acute Exercise</brief_title>
  <official_title>Placebo Controlled Phase II Clinical Trial: Safety and Efficacy of Combining Intranasal Insulin &amp; Acute Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Michigan State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if physical activity engagement alters the dose-response profile and safety of
      administration of insulin into the intranasal mucosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a randomized placebo controlled double-blind pre-posttest design, participants will be
      randomly assigned to receive a dose of either 0, 20, 40, 60, 80, 100, or 120 IU of NovoLog
      insulin aspart prior to being randomized into participating in a 20 minute session of either
      moderate-intensity aerobic exercise or a passive control condition. The efficacy of the
      intranasal insulin for inducing alterations in cognition will be assessed using both
      behavioral and neuroelectric measures. The safety of the protocol will be assessed using a
      symptom questionnaire assessing common symptoms of altered blood glucose and common side
      effects of intranasal insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Random allocation to a dose of intranasal insulin (0, 20, 40, 60, 80, 100, 120) Within each dose, random allocation to exercise or control activity.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind, placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Behavioral Index of Inhibitory Control</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The change from pre-to-posttest in behavioral metrics of performance (RT and response accuracy) on a flanker test of inhibitory control. A more negative change in RT and a more positive change in response accuracy would indicate a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Neuroelectric Index of Attention</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude). A larger change in P3b amplitude would indicate a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Behavioral Index of Sustained Attention</measure>
    <time_frame>Prior to intranasal insulin administration relative to 30 minutes following</time_frame>
    <description>The change from pre-to-posttest in behavioral metrics of performance (RT and response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more negative change in RT and a more positive change in response accuracy would indicate a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of symptom manifestation at any point during the protocol</measure>
    <time_frame>During the 20 minute exercise/control period and the cognitive assessments.</time_frame>
    <description>The manifestation of symptoms associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of symptom manifestation following the protocol</measure>
    <time_frame>Immediately following the completion of the post-test cognitive assessments</time_frame>
    <description>The manifestation of symptoms associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Insulin</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Passive Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 minute sedentary control period during which participants watched an emotionally neutral video.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo into the intranasal mucosa</intervention_name>
    <description>6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 IU NovoLog Insulin aspart into the intranasal mucosa</intervention_name>
    <description>6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer</description>
    <arm_group_label>Acute Exercise</arm_group_label>
    <arm_group_label>Passive Control</arm_group_label>
    <other_name>NovoLog Insulin aspart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must be over the age of 18..

          2. Participants must have normal or corrected-to-normal vision in order to complete the
             cognitive task.

        Exclusion Criteria:

          1. Lack of consent.

          2. Presence of any major neurological health issues, brain trauma, or concussion with
             loss of consciousness assessed through a health history and demographics
             questionnaire.

          3. Type I or Type II Diabetes

          4. Self-reported pregnancy

          5. Currently has any type of inflammation or blockage of the nasal passageways (i.e.
             allergies or a cold affecting the sinuses).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew B Pontifex, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Kinesiology</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Michigan State University</investigator_affiliation>
    <investigator_full_name>Matthew B. Pontifex, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Intranasal Insulin</keyword>
  <keyword>Cognition</keyword>
  <keyword>Exercise</keyword>
  <keyword>Physical Activity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing will be by request and approval of the Michigan State University Human Research Protections Program with the provision of a data-safety and sharing agreement. No individually identifiable information will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available following primary publication of the results.</ipd_time_frame>
    <ipd_access_criteria>By request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

